HCA Healthcare plans senior notes offering

NASHVILLE - HCA Healthcare, Inc. (NYSE: NYSE:HCA) announced today that its subsidiary, HCA Inc., is planning to offer senior notes, pending market conditions. The specifics of the notes, including maturity date, interest rate, and principal, will be determined based on the prevailing market situation at the time of the notes' pricing.

The healthcare company intends to utilize the proceeds from this debt offering for general corporate purposes. This may encompass repaying existing borrowings under its senior secured asset-based revolving credit facility.

The transaction's bookrunners include Citigroup Global Markets Inc., BofA Securities, Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The offering will be conducted in accordance with an effective shelf registration statement already on file with the Securities and Exchange Commission (SEC).

Prospective investors can obtain the preliminary prospectus supplement and the accompanying prospectus from the bookrunning managers. These documents are also accessible electronically on the SEC's website.

HCA has made it clear that this press release does not serve as an offer to sell or a solicitation to purchase the senior notes or any other security. The company will not engage in sales where such actions would be unlawful prior to the necessary registration or qualification under the securities laws of any jurisdiction.

The information in this announcement includes forward-looking statements regarding the anticipated use of the offering's proceeds. HCA has stated that it does not take on the obligation to update any information following the release date. These statements are based on current expectations and projections about HCA's industry and management's beliefs.

As with any forward-looking statements, they are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected.

This news article is based on a press release statement from HCA Healthcare.

In other recent news, HCA Holdings has reported strong second-quarter performance for 2024, with adjusted earnings per share increasing by 28% to $5.50. The company has also updated its full-year revenue projection to between $69.75 billion and $71.75 billion. Adjusted EBITDA for the year is expected to range between $13.75 billion and $14.25 billion, with share buybacks anticipated to reach approximately $6 billion, contingent on market conditions.

This follows various investment firms, including Oppenheimer, Truist Securities, Mizuho Securities, and RBC Capital Markets, adjusting their price targets for HCA Holdings, reflecting confidence in the company's growth trajectory and potential for increased profitability. These recent developments provide a snapshot of the current standing of HCA Healthcare in the industry.

InvestingPro Insights

As HCA Healthcare (NYSE: HCA) explores the financial markets to issue senior notes, investors and analysts are keeping a close watch on the company's performance metrics and strategic moves. InvestingPro data reveals a robust financial profile for HCA, with a significant market capitalization of $91.08 billion and a trailing twelve months revenue as of Q2 2024 amounting to $68.35 billion, marking a revenue growth of 10.38%.

The company's commitment to shareholder returns is evident, as reflected in a dividend yield of 0.75% and a dividend growth of 10.0% over the last twelve months as of Q2 2024.

Two key InvestingPro Tips offer additional insight into HCA's current position in the market. Firstly, HCA has been recognized for its consistency in raising its dividend for three consecutive years, signaling confidence in its financial health and commitment to providing shareholder value.

Secondly, the company's stock is currently trading near its 52-week high, with a price that's 95.54% of the peak, showcasing a strong market performance. For investors seeking more comprehensive analysis, there are 11 additional InvestingPro Tips available, which can be found on the dedicated HCA page at InvestingPro.

These insights, coupled with HCA's strategic financial maneuvers, such as the planned senior notes offering, provide a clearer picture of the company's financial standing and future outlook. With a next earnings date set for October 29, 2024, stakeholders will be keen to see how these strategic efforts translate into financial results for the healthcare giant.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.